Owing to its lineage and differentiation stage-restricted expression, CD77 has been mooted as a therapeutic target in Burkitt lymphoma (BL). The recognition that the globotriaosyl moiety of this neutral glycosphingolipid is a receptor for Escherichia coli-derived Verotoxin-1 (Shiga-Like Toxin-1) offers a potential delivery system for the attack. Here we show that CD77-expressing Group I BL cells which are normally susceptible to activation-induced death on binding Verotoxin-1 B chain are protected in the presence of CD40 ligand. Ectopic expression of either bcl-2 or bcl-x L also afforded resistance to the actions of the B chain. In total contrast, neither of the survival genes nor a CD40 signal ± even when acting in concert ± protected against killing mediated by the holotoxin. These findings indicate that while therapeutic modalities for CD77-expressing B cell tumors (which include follicular lymphoma) based on the use of Verotoxin-1 B chain might be compromised by the activation of endogenous or exogenous survival pathways, those exploiting the holotoxin should be left unscathed. Cell Death and Differentiation (2000) 7, 785 ± 794.
Introduction
Verotoxin-1 (VT-1) produced by the enteropathogenic O157 strain of Escherichia coli binds selectively to the a-D-gal- 1 ± 4 Expressed on subsets of endothelial, mesangial, and epithelial cells, the surface representation of CD77 on hematopoietic cells ± with the exception of subtypes of erythrocytes and some low level expression on monocytes ± is restricted to centroblasts, cells that constitute the proliferating B cell compartment of germinal centers (GC) located within secondary lymphoid organs. 5 ± 11 From its cell line-restricted reactivity and an inability to bind recirculating normal B cells, the prototype CD77 mAb, 38.13, was initially designated as defining a moiety termed`BLA', or Burkitt Lymphoma Antigen. 12 Based partly on their mutual expression of CD77, BL cells are now deemed to represent phenotypic tumor equivalents of normal GC B cells. 13, 14 A large proportion of follicular lymphoma also appears to remain faithful to their normal counterparts by displaying CD77 on the tumor cell surface. 15 VT-1 is composed of an A subunit non-covalently associated with a pentamer of B subunits. The A subunit itself is further divided into a catalytic A1 region and a B chain-binding A2 region by a furin cleavage site. Cleavage at this site is important for optimal activation of toxin during cellular uptake. 16 CD77 permits the cellular entry of VT-1 through an initial binding of the pentameric B subunits of the holotoxin. Subsequent endocytosis of toxin to the endoplasmic reticulum, and membrane translocation to the cytosol, results in the inactivation of ribosomes by the toxin's catalytic A1 subunit. This inactivation involves a specific depurination of 28S ribosomal RNA which renders the ribosomes unable to function in protein synthesis: an event which ultimately leads to the death of the cell. 16, 17 VT-1 has thereby been mooted as a potential delivery system for toxin-based therapy of CD77-expressing lymphoma: indeed, a range of BL cell lines have been shown to die on exposure to the holotoxin in culture. 9, 18 In addition to the ribosome-inactivating properties of the A chain, it was found that B chain pentamer ± when present at sufficiently high concentration ± was, of itself, able to deliver a death signal to BL cells. 18 Subsequent studies using the 38.13 antibody indicated that the cross-linking of CD77 initiated an intracellular signaling cascade (involving a rise in cytosolic Ca 2+ and the generation of ceramide) which culminated in the induction of apoptosis. 9, 19 Thus it appeared that therapeutic attack on CD77-expressing lymphoma independent of VT-1 A chain might now be feasible.
Normal GC B cells display both in situ and in vitro a high propensity for spontaneous apoptosis, a process reflecting the need to select for high affinity mutations that target the V region genes in proliferating centroblasts. 11 The constitutive B cells of GC fail to express the pro-survival protein Bcl-2, a feature retained by BL cells.
histology reflecting the presence and activity of tingible body macrophages that normally colonize GC in order to manage the high rate apoptosis occurring at these sites.
11,25 ± 27 Moreover, BL cell lines in early passage that remain faithful to the biopsy phenotype (termed`group I') are both Bcl-2-negative and can be readily prompted into apoptosis by a variety of signals including those induced by antigen-receptor cross-linking. 23,28 ± 31 Although BL arising in endemic areas invariably harbor Epstein-Barr virus (EBV), freshly-isolated tumor cells and group I lines derived from them fail to express EBV genes involved in B cell immortalization. 32 ± 34 On long-term culture, however, such lines display`phenotypic drift' and ultimately give rise to group III lines as a result of full expression of EBV transforming genes. 33, 34 This is accompanied by the appearance of Bcl-2 protein and a subsequent resistance to antigen-receptor-dependent apoptosis. 23, 29 Introduction of bcl-2 directly into group I cells by gene transfection has confirmed the central importance of Bcl-2 to the anti-apoptotic phenotype that emerges. 22, 23 Follicular lymphoma is quite different from BL being characterized by intrinsic high survival driven by the influence of deregulated bcl-2 that arises from the 14 : 18 chromosomal translocation that defines around 90% of cases. 35, 36 This wired-in survival pathway may underlie the observed difficulty in eradicating the tumor population in this disease. 37 Other survival mechanisms for normal and lymphoma B cells exist. For example, the bcl-2 related gene bcl-x L can offer protection against apoptosis in some scenarios. 38 ± 41 Extracellular signals can also engender protection. For both normal GC B cells and BL cell lines, the most potent of these is provided by CD40 ligand (CD40L) activating its receptor, CD40, on the target cell. 20, 21, 29, 31 CD40L ± a member of the TNF family ± has been characterized as an inducible surface molecule of T-helper cells although a number of studies are now indicating its presence on at least subsets of normal and malignant B cells. 42 ± 45 Thus B lymphoma cells may receive survival prompts both from infiltrating T cells and, potentially, via autocrine/juxtacrine modes.
The design of therapeutic strategies should take account of both the intrinsic and extrinsic means by which a tumor could circumvent the desired result: namely, cell death. Using BL as the model for CD77-expressing lymphoma, we have explored the potential impact of the known survival pathways exploited by B cells on their response to VT-1. The findings demonstrate that these would succeed in protecting lymphoma cells from VT-1 B chain. They would, however, be thwarted when eliciting A chain-dependent killing with the holotoxin.
Results

CD77-dependent sensitivity to cell death is VT-speci®c
Physiological expression of CD77 on B lymphocytes is restricted to those with an apoptotic phenotype leading to the suggestion that its presence may be an intrinsic component of their capacity for programmed cell death (PCD). 9, 46 We assessed here whether the presence of CD77 on BL lines was requisite to their ability to undergo activation-induced PCD while attempting to confirm its necessity for VT-1-mediated killing. This was facilitated by the observation that the L3055 group I BL line maintained in early passage comprised a dual population of CD77 pos and CD77 neg cells at an approximate 2 : 1 ratio (Figure 1a ). Exposure of this line to 100 ng/ml VT-1 for 48 h led to the disappearance of the CD77 pos fraction leaving a viable population that was exclusively CD77 neg ( Figure 1b) . It should be noted that with increasing passage, the percentage of CD77 pos cells in untreated L3055 cultures fell steadily from around 70% in early passages (530) to approximately 30% in later ones (460). The growing proportion of cells that remained viable following exposure to VT-1 closely reflected the increasing number of CD77 neg cells present as the cultures progressed (data not detailed). This not only highlights the specificity of VT-1 for CD77-expressing cells but also indicates that the CD77 neg population emerging post-VT-1 exposure did not arise simply as a consequence of globotriaosylceramide down-regulation at the cell surface: this conclusion was supported by the finding that VT-1 treatment of a group I line where cells were uniformly CD77 pos (Mutu I) failed to yield a viable CD77 neg subpopulation (n=4). When assessed for its ability to respond to VT-1 by the cessation of DNA synthesis (both an indicator of cell killing and a prelude to apoptosis for these cells 24, 31 ) the wild-type population displayed a dose-dependent inhibition that by 24 h reached a maximum of around 70% with VT-1 concentrations of 10 ng/ml and above (Figure 1c) . Extending exposure to 48 h failed to increase significantly the extent of this inhibition. By contrast, the VT-1 selected CD77 neg cells were resistant to VT-1-dependent inhibition whether measured at 24 or 48 h (Figure 1d ). While the CD77 neg cells were similarly refractory to cessation of DNA synthesis promoted by VT-1 B chain, they remained fully sensitive to the inhibitory effects of cross-linking antigen receptor, elicited here by antibody (BU1) to sIgM (data not detailed). The outcome of these treatments as revealed by the inhibition of DNA synthesis was mirrored in a loss of cell viability and/or the appearance of apoptotic nuclei as assessed by visualizing acridine orange-stained cells ( Table 1 ). The latter measurement was significant only for cells exposed to anti-IgM or B chain: the overwhelming majority of cells treated with VT-1 holotoxin had the appearance of lysis or necrosis rather than apoptosis. These data reveal that resistance to killing of group I BL lines resulting from a loss of CD77 is exclusive to VTmediated pathways.
Expression of bcl-2 and bcl-x L confer resistance to VT-1 B chain but fail to protect from holotoxin L3055 cells were forced to express the bcl-2 or bcl-x L genes by generating stable transfectants under the influence of the human EF-1a promoter. A clone transfected with empty vector was established as a control. Another group I BL line, Mutu I, was used to establish a similar set of transfectants. Unlike L3055 cells, Mutu is an EBV-harboring BL line that on long term culture progresses to a group III phenotype. 29, 34 The Mutu III line was also included for study. The status of Bcl-2 and Bcl-x L expression among the different lines was confirmed by Western blotting as illustrated in Figure 2 . It should be noted that the Mutu III cells contained a significant level of constitutively expressed Bcl-2 protein albeit lower than that found in the bcl-2-transfected lines.
Results presented in Figure 3 show that both Bcl-2 and, to a lesser but still significant extent, Bcl-x L protected L3055 cells from cessation of DNA synthesis induced by antibody to sIgM. They each similarly protected from the inhibitory actions of VT-1 B chain. When assessed for sensitivity to VT-1 holotoxin, neither Bcl-2 nor Bcl-x L was seen to afford protection to L3055 cells. The clone selected for the control vector showed a somewhat greater susceptibility than that of wild-type L3055 cells to both VT-1 B chain and holotoxin ( Figure 3 ).
While Mutu I cells are relatively resistant to growth inhibition and programmed death mediated via soluble antiIgM (unpublished observation) they can be encouraged into apoptosis by the calcium ionophore, ionomycin. 29 It can be seen from Figure 4 that Bcl-2 and Bcl-x L each afforded protection to Mutu I cells from the effects not only of ionomycin but also of VT-1 B chain. Neither Bcl-2 nor Bclx L was able to offer resistance to Mutu I cells from VT-1 holotoxin ( Figure 4 ). Mutu III cells displayed a modest cessation of DNA synthesis in response to holotoxin but were fully resistant to both VT-1 B chain and the calcium ionophore.
Effects monitored by cessation of DNA synthesis were again reflected in the appearance of death and/or apoptotic cells ( Figure 5 ). These results confirmed the protection afforded by Bcl-2 and Bcl-x L to L3055 cells from apoptotic death induced by cross-linking sIgM and following exposure (2) 9 (5) 12 (1) 43 (10) 92 (5) 50 (14) 94 (6) 51 (8) 64 (11) 16 (2) 13 (4) 62 (12) 69 (8) 11 (5) 15 (4) 10 (3) 12 (5) 16 (4) 15 (2) 49 (9) 82 (17) 68 (15) 83 (10) 58 (15) 60 (4) 13 (1) 16 (5) L3 wild-type or CD77 neg cells as described in Figure 1 were cultured for times indicated in the presence of: control medium (CM); BU1 (anti-IgM, 500 ng/ml); VT-1 B chain (B chain, 100 mg/ml); or VT-1 holotoxin (VT-1, 30 ng/ml). Results shown are means of triplicate experiments with S.D. indicated in parentheses to VT-1 B chain. Death still ensued on exposure to VT-1 holotoxin however. Bcl-2 and Bcl-x L were again seen to protect Mutu I cells from calcium ionophore-induced death and that engendered by VT-1 B chain but failed to protect from killing mediated via holotoxin. Apart from a minor ± and variable ± population that was susceptible to the holotoxin, Mutu III cells were essentially resistant to all the routes of cell death ( Figure 5 and see below) . It should be noted that with concentrations of VT-1 holotoxin that were sub-optimal, in that they elicited only partial killing of the populations, the death that ensued ± as exemplified here for the L3055 series ± remained primarily non-apoptotic irrespective of survival gene status (Table 2) .
When assessed for CD77 expression, all lines were clearly positive with the exception of Mutu III cells where a minority of cells stained weakly only: the disappearance of CD77 is a hallmark characteristic of a group I to group III transition among BL lines. 13, 34 Interestingly, the bimodal distribution of CD77 expression seen with the L3055 wildtype cells was retained in both the bcl-2 and bcl-x L transfectants while the vector controls displayed a uniformly CD77 high population (data not detailed). All Mutu I transfectants revealed a unimodal high level staining for CD77 (see, for example, Figure 7) .
Thus, among the different lines studied, there was a close correlation between the level of CD77 positivity and susceptibility to VT-1 holotoxin. This association was highlighted by the Mutu III line where the number of dead cells arising in response to VT-1 exposure mirrored closely the proportion of CD77 pos cells detected at the time of analysis ± thus, over four experiments, the following percentages for`death' (as measured by trypan blue dye uptake following 24 h treatment with VT-1) versus`CD77-positivity' (determined by FACS analysis at t=0) were observed: (i) 13% vs 10%; (ii) 26% vs 25%; (iii) 27% vs 24%; (iv) 43% vs 39%. The reason for the variability in CD77 expression seen with Mutu III cells is presently unclear but may relate to the growth phase of the cultures (our own unpublished observations).
CD40 signals discriminate against B chain-and holotoxin-mediated death pathways
The presence of soluble CD40L at 50 ng/ml protected both L3055 and Mutu I wild-type cells from cessation of DNA synthesis mediated by soluble anti-IgM and ionomycin respectively, confirming previous observations. 21, 24, 29 CD40L offered similar protection from VT-1 B-chain but left the actions of VT-1 holotoxin unchecked. CD40 signaling Protection from toxin killing in B lymphoma J Gordon et al failed to protect against the holotoxin even for lines expressing bcl-2 or bcl-x L (data not detailed). Assessments of cell viability once more confirmed these observations ( Figure 6 ). On studying SAV and BL2 ± two other CD77 pos group I BL lines sensitive to sIgM-dependent apoptosis ± there was an identical outcome in the ability of CD40L to protect from death mediated by soluble anti-IgM or VT-1 Bchain while failing to spare them from killing elicited by the holotoxin (Table 3) .
Finally, we asked whether CD40L might be offering protection to the cells from B chain killing by downregulating CD77 expression, a phenomenon previously (2) 26 (6) 37 (6) 22 (5) 25 (4) 40 (8) 56 (9) 35 (7) 38 (9) 59 (10) 84 (11) 54 (7) 58 (12) 11 (4) 5 (2) 0 (0) 2 (1)
9 (4) 10 (2) 1 (1) 4 (2) 16 (6) 14 (5) 1 (1) 7 (4) As for Table 1 reported for group I cells exposed to high concentrations (1 mg/ml) of soluble CD40L for 3 days or more. 24 While cells cultured with CD40L remained sensitive to death promoted by holotoxin, the need for extensive cross-linking of CD77 to elicit A chain-independent killing via CD77 might necessitate that high level receptor expression is maintained for B chain-mediated apoptosis to proceed. 9, 19 Mutu I cells were used for these studies as they displayed a uniformly high CD77 starting population. It is clear from the results presented in Figure 7 that culture of Mutu I cells (here shown for vector controls) with 50 ng/ml of soluble CD40L for either 24 or 48 h did not lead to a disappearance of CD77. Although CD77 levels did start to fall by day 2, expression remained substantive and was unlikely to be limiting: indeed, even after incubation with soluble CD40L, Mutu I vector controls carried higher levels of CD77 than wild-type cells. A similar outcome was obtained for Mutu I cells carrying bcl-2 or bcl-x L (data not detailed).
Discussion
In certain respects, group I BL forced to express bcl-2 ectopically models follicular lymphoma. Both B cell tumors display a GC phenotype with the exception of follicular lymphoma being constitutively Bcl-2 positive due to the deregulation of the bcl-2 gene arising from the 14 : 18 translocation that characterizes this disease. 14, 15, 35, 36 For any therapeutic modality to succeed against this most common of the lymphoma, it needs to overcome the powerful survival influence afforded to B cells by Bcl-2. Moreover, normally Bcl-2 negative BL cells can be prompted by extracellular signals to express the survival protein. 24 To confound matters further, CD40L can stimulate survival pathways in normal and malignant B cells independently of bcl-2. 21 For both human and murine B cells, CD40 engagement can lead to an upregulation of the anti-apoptotic bcl-2 family member, bcl-x L 38 ± 41 Though yet to be proven, the potential for CD40 signaling in B cell lymphoma exists by way of infiltrating T cells and via autocrine/juxtracrine CD40L-CD40 interactions.
± 45
Here we have shown that while activation of either endogenous or exogenous survival pathways spares BL cells from death mediated by the B chain of VT-1, they remain fully susceptible to A chain-dependent killing elicited by VT-1 holotoxin. This extended to cells both ectopically expressing high levels of survival genes and receiving CD40L signals, an important outcome given the finding of Ghia et al that CD40-stimulated up-regulation of bcl-x L in follicular lymphoma may contribute to enhanced survival. 47 Moreover, we have recently reported that normal, Bcl-2 positive, non-germinal center B cells induced to express CD77 by high level engagement of CD40L gain full susceptibility to killing by the holotoxin. 48 The complete resistance to B chain killing exhibited by the Mutu III cell line, while remaining fully susceptible to holotoxin, may have been due to more than the relatively low level of Bcl-2 that was found to be expressed: the EBV-encoded Latent Membrane Protein-1 (LMP-1) protein that is turned on as group I cells progress towards a group III phenotype additionally activates the expression of a zinc finger protein (A20) that can provide independent signaling for cell survival:
49,50 moreover, LMP-1 has been shown to behave ± in many respects ± as a constitutively active CD40 molecule providing further bcl-2-independent, anti-apoptotic potential when expressed. 51 In toto, the above indicate that although therapeutic exploitation of VT-1 B chain for CD77-expressing lymphoma would seemingly have only limited application, that of VT-1 holotoxin appears to hold more universal appeal.
The capacity of the survival pathways to discriminate against B chain-and A chain-dependent killing is likely to reflect the different modes of cell death elicited by the two. High concentrations of pentameric B chain are required to achieve killing of group I BL cells [Mangeney et al 18 and data reported herein]. The ensuing cell death has been described previously as arising from an apoptotic pathway. 18 This we confirmed by demonstrating the generation of apoptotic nuclei as revealed by visualization of acridine orange-stained cells. Moreover, the ability to protect against this route of killing by anti-apoptotic signals in itself reinforces the notion that B chain triggers programmed death in these cells. It was recently reported that on crosslinking 38.13 antibody bound to CD77, an intracellular signaling cascade is initiated involving a rise in cytosolic Ca 2+ and the generation of ceramide. 9, 19 Boht have been implicated as components of apoptotic cell death in B lymphoma cells. 28, 52 The A chain of VT-1 promotes cell death by inhibiting protein synthesis as a consequence of modifying ribosomal RNA. 16, 17 While still requiring the B chain to gain entry into a target cell, it is questionable whether CD77-dependent pathways additional to those of simple binding and This statement is based on the observation that VT-1 holotoxin kills cells at concentrations considerably less (510 ng/ml) than those required for B chain to be active (410 mg/ml). The involvement of an apoptotic component to holotoxin-mediated death is not ruled out however. It was recently shown that Pseudomonas endotoxin (PE) ± which similar to VT-1 can kill target cells via A chain-dependent inhibition of protein synthesis ± also increases caspase activity and induces PARP cleavage in a neoplastic epithelial cell line. 53 Thus, like PE, VT-1 may be exploiting two routes to cell death. Indeed, although for the lines used in the present study we were unable to detect significant induction of fragmented nuclei in response to the holotoxin, apoptotic morphology has been reported for other BL cells exposed to low doses of VT-1. 18 Despite this, as evidenced from the inability of either CD40 signals, Bcl-2, or Bcl-x L to protect, it seems that even though VT-1 A chain might be capable of stimulating components of apoptosis, this pathway is redundant to the ultimate outcome: i.e., the killing of the cell. A similar conclusion was reached from a study on the VT-1 killing of endothelial cells where caspase inhibitors were able to reverse the measures of apoptosis made while death proceeded as normal. 54 For group I BL cells, CD77 was found not to be requisite for the expression of an apoptotic phenotype per se. This possibility had been raised previously in regard to both BL and their normal GC B cell equivalents: 9, 46 indeed, a mechanistic basis for this could be envisaged through a potential pro-apoptotic activity being generated from the intracellular ceramide moiety of CD77. Nevertheless, while the CD77 neg fraction of the L3055 line was clearly refractory to killing via both VT-1 B chain and holotoxin they remained fully susceptible to apoptosis induced by cross-linking their sIgM. The retention of an apoptotic capacity by VT-1-selected CD77 neg cells is encouraging for the outcome of any VT-based therapy where similar escape variants could potentially arise on treating patients with the toxin in vivo.
Having established a preference for exploiting the holotoxin in any CD77-targeted attack on B cell lymphoma, consideration must be given to the danger of damaging other cells, especially CD77 pos endothelial cells of the kidney. Verotoxin-producing Escherichia coli strains have been strongly implicated in the etiology of hemolytic uremic syndrome, the leading cause of pediatric acute renal failure. 55, 56 However, reflecting the age distribution of this problem, some comfort is given by the finding that VTbinding, while it can be observed in the infant glomerulus, is not detectable in the adult where, instead, it is restricted to tubules. 5 We are currently addressing whether even lower concentrations of VT-1 than those used in the present study might act in synergy with other B cell-directed therapeutics and thereby minimize any deleterious effects on non-B cells. CD20 antibodies, already being used with promise in follicular lymphoma, are a consideration here. 57 Finally, we could consider mutating the VT-1 A chain to eliminate the furin-cleavage site which is important for A chain activation during cell cycle entry 16 and to substitute alternative residues that would be susceptible to B cellspecific enzymes. Our finding that VT-1 holotoxin kills lymphoma cells even when confronted with powerful survival factors indicates that these possibilities warrant serious attention.
Materials and Methods
Reagents
The BU1 mouse IgG2a monoclonal antibody to human IgM was produced from the hybridoma in the Department of Immunology, University of Birmingham, and purified by ion-exchange chromatography on DE52 (Whatman Ltd, Maidstone, UK). Asitic fluid containing rat IgM anti-CD77 mAb (38.13) was a kind gift from Dr J Wiels (Institut Gustav-Roussy, Villejuif, France) and control ascitic fluid containing rat IgM anti-DNP was obtained from Serotec (Oxford, UK). 38.13 ascitic fluid and control rat IgM ascitic fluid were conjugated to FITC by standard techniques. In some experiments, unconjugated 38.13 mAb purchased from Serotec was used. Ionomycin was obtained from Calbiochem-Novabiochem (Nottingham, UK). Soluble trimeric CD40L was generated as an isoleucine zipper construct as described by Morris et al.
58
Puri®cation of Verotoxin-1 and VT-1 B chain
Verotoxin-1 was prepared from periplasmic extracts of E. coli JM105 transformed with the expression plasmid pSLT (a plasmid encoding the Verotoxin-1 operon under the control of the lac promoter). Cells were grown in Luria broth supplemented with 100 mg/ml ampicillin to an OD 600 of 0.6 (measured with a Shimadzu UV-160 spectrophotometer). Expression was induced by the addition of isopropyl b-D-thiogalactopyranoside (1 mM final concentration) and allowed to proceed for 3 h. Cells were harvested by centrifugation (10 min at 75006g), washed in 600 mM sucrose, 300 mM Tris/HCl (pH 8.0), 1 mM EDTA and 0.5 mM MgCl 2 , and resuspended in 1 mM Tris/HCl, pH 7.5. After incubation on ice for 10 min, cell debris was removed by centrifugation (15 min at 15 0006g). The supernatant was filter-sterilized by passage through a 0.2 mm filter and applied to a 6 ml globotriose-Sepharose affinity column 59 equilibrated with 0.5 M NaCl in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ). The column was washed with 40 volumes of 0.5 M NaCl in PBS prior to eluting VT-1 with 6 M guanidine.HCl. Fractions of 1 ml were collected and immediately dialyzed against PBS to remove the denaturant. VT-1 B chain was isolated exactly the same way. The plasmid used here was pSBC32 which contains the coding sequence for the B chain in the high level expression vector pKK233-2 and was a kind gift of Dr SB Calderwood. 60 
Cell lines
Group I BL cell lines L3055 (EBV neg ), BL2 (EBV neg ), SAV (EBV pos ), and Mutu I (EBV pos ) were maintained in early passage as previously described. 24, 29 Late passage Mutu III cells were also included for study. 29 Cells were maintained in continuous culture with RPMI 1640 supplemented with 10% pre-screened FCS (Bio-Whittacker, Wokingham, UK), 5000 IU/ml penicillin, 5 mg/ml streptomycin (Gibco/BRL, Paisley, UK) and 200 mM glutamine (Gibco/BRL). Stable bcl-2 transfectants were obtained as described previously. 22, 23 Stable bcl-x L transfectants were derived by electroporation of the plasmid vector pEF-MC1neopA 61 containing the bcl-x L cDNA followed by selection of cells in G418 (Sigma, Poole, UK). Immunoblotting for Bcl-2 and Bcl-x L was carried out as detailed elsewhere. 23, 24 From the lines established, those showing high level expression of the genes transfected were chosen for study.
Selection of CD77
neg cells L3055 cells were cultured at a concentration of 4610 5 /ml for 48 h in the presence of VT-1 at 100 ng/ml. Dead cells were removed by centrifugation on Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). Remaining viable cells were collected from the interface, washed three times in culture medium and used as`CD77 neg cells' in the experiments described.
Flow cytometric analysis of CD77 expression
Cells were harvested after culture under the conditions indicated in the text. Cells were washed once in PBS with 0.1% BSA and 0.01% sodium azide (FACS buffer) before direct or indirect immunofluorescence analysis was performed. Briefly, cells were labeled by a 30 min incubation on ice with either directly-conjugated rat 38.13 mAb or unconjugated mAb that was detected by an additional second stage incubation with FITC-conjugated anti-rat IgM Ab (Serotec). In both cases, rat IgM anti-DNP was used as the control. Cells labeled either directly or indirectly were washed once and resuspended in FACS buffer. Flow cytometry data were obtained using an Epics-XL flow cytometer (Beckman Coulter, Miami, FL, USA). Viable cells were gated according to forward (FSC) and side (SSC) light scatter settings. Data were processed and analyzed using WinMDI software (Scripps Research Institute, La Jolla, CA, USA).
Measurement of DNA synthesis
DNA synthesis was determined by [ 3 H]thymidine incorporation. 31 After culture of 5610 4 cells per 200 ml with additions as specified, wells were pulsed for the final 4 h with [ 3 H]thymidine (Amersham Interanational, Amersham, UK, 10 mCi/ml in culture medium, 50 ml per well) and harvested on a Skatron cell harvester (Helis Bio Ltd, Newmarket, UK). All assays were performed in quadruplicate with replicates usually being within 10% and always within 15% of each other.
Cell viability and apoptosis assays
Cell viability was assessed by a standard trypan blue dye exclusion assay. 31 Apoptosis was determined by staining treated cells with acridine orange and visualizing nuclear morphology exactly as described previously. 22 Viable cells display a homogenous chromatin staining pattern whereas apoptotic cells show characteristically condensed and fragmented chromatin. Each determination was carried out on scoring 100 cells in duplicate.
